￼The company completed and received approval of its small-scale aseptic filling line in CordenPharma Caponago. This addition to the existing terminal sterilization capabilities of the manufacturing facility will support customer development and commercial programs by providing expert service in aseptic-filling of liquid and lyophilized vials and pre-filled syringes for small molecules and peptides.
CordenPharma has also completed and received approval of expanded development capabilities (CTD2) for mid-scale—up to 20 kg—contained capacity of highly potent and oncology oral dosage forms in its CordenPharma Plankstadt manufacturing facility. This new and expanded capability provides customers a complete offering in the contained manufacturing of oral dosage from grams to 150 Kg.
“These new investments in oral and aseptic development capacities strengthen our ability to serve customers earlier in the pharmaceutical value chain,” said Ernesto Petroselli, president, CordenPharma. “They are a clear indication of our overall commitment in responding to customers’ needs and are perfect complements to our existing API and drug product service offerings within our highly potent, oncology and injectables platforms.
In addition, Mr. Petroselli said there will be further capacity expansion in the second half of 2016 with the completion ￼of a second pharmaceutical oncology suite in CordenPharma Latina to provide extended ￼supply chain manufacturing services spanning development to commercial scale.